Capital Impact Advisors’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Capital Impact Advisors’s Portfolio SGNT Stock Details SGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-28,587	Closed	-$438K	–	292
2015 Q3	$438K	Hold	28,587	–	–	0.22%	173
2015 Q2	$695K	Hold	28,587	–	–	0.32%	137
2015 Q1	$665K	Buy	28,587 +21,525	+305%	+$570K	0.3%	145
2014 Q4	$177K	Hold	7,062	–	–	0.08%	138
2014 Q3	$220	Hold	7,062	–	–	﹤0.01%	95
2014 Q2	$183K	Buy	+7,062	New	+$157K	0.14%	103

Other funds holding SGNT

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

PCM

Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Impact Advisors's SGNT Position: Q4 2015 in Review

Capital Impact Advisors sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q4 2015, closing a stake of 28,587 shares — an estimated $438K sold.

Capital Impact Advisors first reported a position in SGNT in Q2 2014 and held it in 6 quarters. The position peaked at $695K in Q2 2015. 134 funds tracked by Wall St. Rank hold SGNT as of Q4 2015.

Capital Impact Advisors reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q4 2015 after selling out during the quarter.
Capital Impact Advisors sold 28,587 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q4 2015, an estimated $438K.
Capital Impact Advisors first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2014 and held it in 6 quarters.
Capital Impact Advisors's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $695K in Q2 2015.
134 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q4 2015.

Based on Capital Impact Advisors's 13F filing for Q4 2015, filed 11 Jan 2016.